Intermediate-affinity CD19-directed CAR T cell product obecabtagene autoleucel demonstrates favourable safety and efficacy in R/R B-ALL - Rawan G. Faramand; Frederick L. Locke (Nature Reviews Clinical Oncology, 2025)